Equities analysts expect that Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) will post earnings per share of ($0.64) for the current quarter, according to Zacks. Two analysts have made estimates for Dicerna Pharmaceuticals’ earnings. The highest EPS estimate is ($0.28) and the lowest is ($0.80). Dicerna Pharmaceuticals reported earnings per share of ($0.68) during the same quarter last year, which would indicate a positive year over year growth rate of 5.9%. The business is expected to announce its next quarterly earnings results on Thursday, March 29th.
Zacks Investment Research’s earnings per share averages are an average based on a survey of analysts that follow Dicerna Pharmaceuticals.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.22). The firm had revenue of $0.47 million for the quarter. Dicerna Pharmaceuticals had a negative return on equity of 293.25% and a negative net margin of 5,895.26%. The firm’s revenue for the quarter was up 192.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.68) earnings per share.
In related news, Director Bain Capital Life Sciences Inv purchased 285,000 shares of the company’s stock in a transaction that occurred on Monday, December 18th. The shares were purchased at an average price of $7.00 per share, with a total value of $1,995,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 29.41% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the business. Northern Trust Corp grew its stake in Dicerna Pharmaceuticals by 6.1% during the 2nd quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 2,094 shares in the last quarter. Vanguard Group Inc. grew its stake in Dicerna Pharmaceuticals by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock valued at $1,078,000 after acquiring an additional 14,517 shares in the last quarter. Palo Alto Investors LLC grew its stake in Dicerna Pharmaceuticals by 4.0% during the 2nd quarter. Palo Alto Investors LLC now owns 500,913 shares of the biopharmaceutical company’s stock valued at $1,588,000 after acquiring an additional 19,394 shares in the last quarter. Birchview Capital LP grew its stake in Dicerna Pharmaceuticals by 125.0% during the 3rd quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock valued at $259,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Deschutes Portfolio Strategy LLC purchased a new position in Dicerna Pharmaceuticals during the 3rd quarter valued at about $575,000. 42.63% of the stock is currently owned by institutional investors.
Dicerna Pharmaceuticals (DRNA) traded down $0.05 during trading hours on Thursday, reaching $9.31. The company had a trading volume of 241,700 shares, compared to its average volume of 361,400. The firm has a market capitalization of $256.79, a price-to-earnings ratio of -2.71 and a beta of 2.85. Dicerna Pharmaceuticals has a 1 year low of $2.42 and a 1 year high of $10.24.
ILLEGAL ACTIVITY WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/01/04/zacks-brokerages-anticipate-dicerna-pharmaceuticals-inc-drna-to-announce-0-64-eps.html.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.